Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Theranos Founder Announces New Blood Testing Device

XTALKS VITALS NEWS

Elizabeth Holmes

With Holmes’ impending ban set to take effect on September 5, some had expected her to speak about the validity of the Edison device at the AACC conference.

Tweetables from this article:

Tweet: CEO and founder Elizabeth Holmes unveiled the details of a new blood testing device, called the miniLab http://ctt.ec/0b4f3+CEO and founder Elizabeth Holmes unveiled the details of a new blood testing device, called the miniLab.

Tweet: Theranos' miniLab to analyze small-volume blood samples using multiple different diagnostic methods http://ctt.ec/MlQKb+Theranos' miniLab to analyze small-volume blood samples using multiple different diagnostic methods.

Share this!

August 3, 2016 | by Sarah Massey, M.Sc.

At the American Association for Clinical Chemistry (AACC) conference this week, Theranos CEO and founder Elizabeth Holmes unveiled the details of a new blood testing device, called the miniLab. The device was designed to analyze small-volume blood samples using multiple different diagnostic methods in a single desktop machine.

The device is not yet approved by the US Food and Drug Administration (FDA), however Holmes presented data based on the device’s ability to analyze capillary blood samples at the AACC conference. Holmes recently received a two-year ban from owning and operating a blood testing business from US regulators, after violations were identified at two Theranos testing facilities.

While Theranos’ Edison device was touted as a revolutionary tool with the potential to diagnose multiple conditions from a single drop of blood, the company has since fallen from grace. An inspection of the company’s California testing facility last year – conducted by the Centers for Medicare and Medicaid Services (CMS) – highlighted a number of issues with Theranos’ blood testing practices.



In an effort to find a solution to those concerns, Theranos voided tens of thousands of blood test results which were released between 2014 and 2015. Despite their efforts to make amends, the CMS banned Holmes from the medical laboratory business for two years, and the Newark lab’s certification was revoked.

With Holmes’ impending ban set to take effect on September 5, some had expected her to speak about the validity of the Edison device at the AACC conference. Instead, Holmes discussed the company’s newest miniLab device.

“We’re pleased to share our technologies with the entire laboratory industry,” said Holmes. “It’s the beginning of the next phase of the company, as we introduce our technologies to the world. We also will be working with academic institutions and other independent parties to validate and publish our results.”

Holmes has since faced additional criticism for failing to speak to the inefficiencies in Theranos’ current blood testing methodologies. She has also not provided any peer-reviewed studies on neither the Edison nor the miniLab device.


Keywords: Blood Test, Medical Device, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.